Risperidone

Quick links to important sections

Risperidone

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risperidone

Property Description
Active ingredient Risperidone
Form Oral tablets, oral solution, injectable suspension
Pharmacological class Atypical Antipsychotic (Second Generation)
Common use Mental and emotional stability
Origin Synthetic compound (benzisoxazole derivative)

Risperidone is a synthetic psychopharmacological agent known by its international nonproprietary name (INN) of Risperidone. It is a single-ingredient product classified as an antipsychotic agent, which is a type of medicine used to manage certain mental health conditions. Risperidone belongs to the subclass of atypical antipsychotics, also known as second-generation agents. It is clinically recognized for its role in supporting the stabilization of complex emotional states across a wide range of patient ages, from adults to carefully monitored pediatric cases.

What Type of Medicine is Risperidone?

Risperidone is a modern, synthetic compound whose chemical structure is identified as a benzisoxazole derivative, a chemical classification that establishes its distinct receptor binding profile. The medication is manufactured in various preparations for both oral and intramuscular administration, primarily as oral tablets, an oral solution (a formulation that simplifies use for patients with swallowing difficulties), and a specialized long-acting injectable suspension. This range of dosage forms provides a choice between daily, direct ingestion and a less frequent, sustained-release mechanism.

Composition and General Purpose of Risperidone

The active ingredient is Risperidone, and its core action is that of a serotonin-dopamine antagonist. This pharmacological principle signifies that the medicine works by regulating the activity of two key chemical messengers in the brain—dopamine and serotonin—specifically through modulation of the D2 and 5-HT2A receptors. This mechanism helps to decrease the activity in pathways thought to contribute to symptoms of severe thought and mood disorders. By promoting a balanced neurochemical environment, the general therapeutic purpose of Risperidone is to help stabilize severe disturbances in thought, perception, and emotional control, thereby supporting clearer cognition and mental stability.

Regulatory References

  1. Risperidone - StatPearls - NCBI Bookshelf
  2. Risperidone: MedlinePlus Drug Information

What side effects are possible with Risperidone?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Risperidone, based strictly on government regulatory sources like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Official Adverse Reaction Listings and Frequency

Adverse reactions are classified by frequency as observed in clinical trials, according to regulatory standards:

Frequency Category Representative Adverse Reactions (by SOC)
Very Common (ge 1/10) Headache, Parkinsonism, Sedation/Somnolence, Insomnia (Nervous/Psychiatric System)
Common (ge 1/100 to < 1/10) Dizziness, Tremor, Akathisia, Weight increased, Hyperprolactinemia, Nausea, Vomiting (Nervous/Metabolism/GI System)
Uncommon (ge 1/1,000 to < 1/100) Seizure, Cerebrovascular accident (CVA), Diabetes mellitus, Hypersensitivity, Priapism (Various Systems)

Serious Adverse Reactions and Safety Constraints

Regulatory labeling highlights specific serious events and safety limitations:

  • Serious Adverse Reactions: Officially documented serious risks include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, and QT Prolongation.
  • Population-Specific Warnings: Official labeling includes a warning of increased risk of mortality and Cerebrovascular Adverse Events (e.g., stroke) when used in elderly patients with dementia-related psychosis (a use not approved by the FDA).
  • Time-Related Patterns: The risk of Tardive Dyskinesia is noted to increase with the duration of treatment and total cumulative dose. Orthostatic Hypotension is often reported during the initial dose titration phase.
  • Contraindication: Risperidone is contraindicated in individuals with known hypersensitivity to the active substance.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

A Risperidone overdose is classified by regulatory authorities as a medical emergency primarily affecting the Central Nervous System (CNS) and cardiovascular systems. Officially documented presentations include severe CNS depression, such as drowsiness and sedation, which can progress to confusion, convulsions, or coma. Neurological signs also involve pronounced Extrapyramidal Symptoms (EPS).

Cardiovascular instability is a critical feature, typically presenting as tachycardia (rapid heartbeat) and hypotension (low blood pressure). More severe complications listed in official labeling include life-threatening ECG abnormalities such as a Prolonged QT interval and Widened QRS. Severe cardiovascular and CNS events are noted as potential outcomes, with increased vulnerability observed in the elderly patient population.

Required Emergency Action and Management

In the event of a suspected or confirmed overdose, the regulatory guidance is to seek immediate medical attention and contact emergency services or a certified poison control center. This urgent action is mandated due to the potential for life-threatening complications.

The management of a Risperidone overdose is entirely symptomatic and supportive, as no specific antidote is known. Official procedures include closely monitoring the patient’s cardiac rhythm and vital signs, ensuring an adequate airway, oxygenation, and ventilation, and correcting hypotension or severe EPS with appropriate supportive measures. Pediatric patients are noted to have an increased risk of severe EPS following overexposure.

Therapeutic Uses of Risperidone

Risperidone is commonly used across domains where additional symptomatic support is needed, applied in clinical settings that involve acute or unstable symptom patterns. It is considered relevant when supportive symptom management is appropriate and supports general well-being during symptomatic phases.

Risperidone is an atypical antipsychotic relevant for easing symptoms across three primary therapeutic areas: Schizophrenia, acute manic and mixed episodes of Bipolar I Disorder, and irritability associated with Autistic Disorder. It is relevant for easing symptom clusters that create noticeable functional strain, such as severe delusions, hallucinations, aggression, and emotional hyperactivity.

Quick Fact: Supportive Relief for Severe Irritability and Psychotic Symptoms

In these contexts, the medication helps address groups of symptoms that may become intense or disruptive, providing symptomatic relief that may assist with maintaining functional stability for adults, adolescents, and children (typically 5 years and older for autism-related use). It is applied in addressing conditions involving episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Risperidone?

The population eligibility for Risperidone is strictly defined by regulatory authorities and is categorized by absolute contraindications, age limits, and physiological status.

Absolute Contraindications

Risperidone is contraindicated for specific populations where use is prohibited by official labeling:

  • Patients with a known hypersensitivity to Risperidone, its active metabolite paliperidone, or any excipients.
  • Elderly patients with dementia-related psychosis, due to an increased risk of death, as stated in a U.S. regulatory Boxed Warning.

Age-Related Eligibility

Use is not established below specific age thresholds for the labeled indications:

  • Schizophrenia: Safety and efficacy are not established in patients under 13 years of age.
  • Bipolar Mania: Safety and efficacy are not established in patients under 10 years of age.
  • Irritability associated with Autistic Disorder: Safety and efficacy are not established in patients under 5 years of age.

Restrictions and Conditional Use

Regulatory documents mandate special caution and a lower initial dose for certain populations:

  • Severe Renal or Hepatic Impairment: Patients with reduced kidney or liver function require dosage adjustments due to altered drug clearance.
  • Pregnancy and Lactation: Use during the third trimester of pregnancy may cause extrapyramidal symptoms or withdrawal in the neonate. Use while breastfeeding is not recommended by some regulators due to drug excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the Risperidone interaction profile based on effects on the body's drug processing and additive pharmacodynamic activity. Risperidone is primarily metabolized by the CYP2D6 enzyme and, to a lesser extent, by CYP3A4, and is a substrate of the P-glycoprotein (P-gp) transporter. Co-administration with substances that inhibit or induce these pathways can alter plasma concentrations of the active antipsychotic fraction.

Strong CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine) increase the plasma concentration of the parent drug, while strong CYP3A4 inducers (e.g., Carbamazepine, Rifampicin) are documented to decrease the total active fraction. Conversely, inhibitors like Itraconazole (a P-gp/CYP3A4 inhibitor) can substantially elevate active concentrations. Regulatory labels state that the Risperidone dosage requires re-evaluation when these strong interacting medicines are initiated or discontinued.

Pharmacodynamic interactions include additive effects with other Centrally-Acting Drugs, which may increase somnolence. Official labeling requires patients to avoid alcohol due to the risk of additive CNS depression. The medication may antagonize the effects of Levodopa and Dopamine Agonists, and it may enhance the effects of drugs with hypotensive potential. For specific populations, caution is noted in elderly patients with dementia co-administered with the diuretic Furosemide.

Mechanism of Action

Dual Receptor Antagonism and Neurochemical Balance

The action of Risperidone is defined by its ability to modulate key neurotransmitter systems in the central nervous system (CNS), primarily through the antagonism (blocking) of two specific receptor types: the Dopamine Type 2 ( D2) and the Serotonin 5- HT2 A receptors. While D2 antagonism limits dopaminergic signaling within the mesolimbic pathway, the high-affinity 5- HT2 A antagonism affects dopamine release in other critical brain regions. This simultaneous, balanced modulation affects the regulation of signal transmission within the targeted CNS pathways.


Mechanistic Additive Effect of the Total Active Moiety

The overall pharmacological activity results from the additive contributions of the parent compound, Risperidone, and its major, active metabolite, 9-hydroxyrisperidone. Both chemical entities share the same D2 and 5- HT2 A receptor antagonism profile, leading to their combined engagement of the receptors. This produces a characteristic pattern of physiological adjustment in neurotransmitter systems.


Secondary Receptor Engagement

In addition to its primary targets, the drug engages mechanisms by blocking alpha1-adrenergic and H1 histamine receptors. This secondary receptor engagement influences vascular tone and wakefulness, representing further downstream physiological consequences of the drug's mechanism of action.

Dosage and Administration Information

How to use Risperidone: Official Administration Guidelines

Risperidone is available for oral administration as tablets, orally disintegrating tablets, and oral solution. It is typically taken once or twice daily, and may be administered with or without food. Adherence to the prescribed titration schedule is a core component of the administration protocol.

Official Dosing Rules

Age Group / Condition Initial Daily Dose (typically once or twice daily) Dose Titration Rules Special Populations
Adults (Schizophrenia) 2 mg Increase by 1-2 mg every 24 hours Severe renal or hepatic impairment: Start at 0.5 mg twice daily.
Adolescents (Schizophrenia) 0.5 mg Increase by 0.5-1 mg every 24 hours Increases above 1.5 mg twice daily must occur at intervals of at least one week for these special groups.

Preparation and Procedural Steps

  • Oral Solution: The prescribed dose should be measured using the provided dosing syringe. The liquid may be mixed with water, coffee, orange juice, or low-fat milk; however, do not mix it with tea or cola. Drink the entire mixture immediately.
  • Orally Disintegrating Tablets (ODT): The ODT should not be pushed through the foil, as this can damage the tablet. The patient must use dry hands to peel back the foil, immediately remove the tablet, and place it on the tongue, where it will quickly dissolve and can be swallowed with or without liquid. The tablet must not be split or chewed.

If a dose is missed, take it as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule; do not double the dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Risperidone

Evidence for use in Schizophrenia

The clinical evaluation of this medicine for schizophrenia involved Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, typically over short intervals of four to eight weeks. Researchers primarily studied adults and adolescents aged 13 and older, examining outcomes related to episodic or acute changes in psychotic symptoms like delusions and hallucinations. Research also describes long-term outcomes, with some studies observing responses over defined time intervals of six months to over a year, focusing on whether the medicine was associated with changes in the frequency of future symptom flare-ups. Data show patterns related to the outcomes monitored in the group receiving the medicine compared to the placebo group. The evidence is limited regarding the sustained impact on long-term functional outcomes beyond the initial short-term symptom monitoring.

Evidence for use in Acute Manic and Mixed Episodes of Bipolar I Disorder

This medicine was studied for acute episodes of Bipolar I Disorder in short-term RCTs, with trials lasting three to four weeks. Research explored short-term symptom changes in patients experiencing conditions involving periods of heightened symptoms (mania or mixed states). The medicine was studied for use as a single agent (monotherapy) and as an addition (adjunctive treatment) alongside established mood stabilizers. The evidence base also includes studies that included children and adolescents aged 10 and older. The follow-up durations were limited, as these studies were predominantly focused on the acute phase, meaning long-term effects are not fully established from controlled trials for preventing future episodes.

Evidence for use in Irritability Associated with Autistic Disorder

This medicine was studied for in cohorts where researchers examined specific irritability-related behaviors, focusing specifically on aggression, severe tantrums, and deliberate self-injury over short-term intervals of approximately eight weeks in children and adolescents (5 to 17 years old). Data show patterns related to measured changes in the group receiving the medicine compared to the placebo group. However, the research describes that the core symptoms of autism (such as social relatedness or communication difficulties) were not the primary focus of these trials, and findings regarding these areas were limited.

Frequently Asked Questions (FAQ)

Common questions about Risperidone (FAQ)

Q: What is the main reason doctors prescribe Risperidone?

A: Doctors primarily prescribe Risperidone for the officially approved indications found in regulatory documents. These indications include treating Schizophrenia, Bipolar I acute manic or mixed episodes, and irritability associated with autistic disorder in certain populations.

Q: Is Risperidone the same type of medication as olanzapine or aripiprazole?

A: Regulatory classification places Risperidone in the same general drug class as olanzapine and aripiprazole. This class is known as second-generation (atypical) antipsychotics.

Q: How long does it usually take to feel the effects of Risperidone?

A: Official information states that the medication is intended to help manage the symptoms of the condition. The full therapeutic benefit and optimal symptom control may develop gradually after starting treatment.

Q: Does Risperidone cause long-term side effects that I should know about?

A: Regulatory warnings highlight the risk of potential long-term adverse effects. These include the development of Tardive Dyskinesia (involuntary movements), Metabolic Changes (like weight gain and high blood sugar), and Hyperprolactinemia (high levels of the hormone prolactin).

Q: Is weight gain a common side effect reported with Risperidone?

A: Yes, weight gain is explicitly listed in official labeling as a common adverse reaction that has been reported in clinical trials. It is monitored as part of the metabolic changes associated with the drug.

Q: Can Risperidone affect my sleep patterns?

A: Regulatory documents indicate that the drug can affect sleep patterns. Both somnolence (drowsiness or tiredness) and insomnia (difficulty falling or staying asleep) are listed among the commonly reported adverse reactions.

Q: Are there any foods or drinks that should be avoided while taking Risperidone?

A: According to official product information, the oral solution should not be mixed with beverages like tea or cola. Additionally, regulatory documents state that alcohol should be avoided while taking the medication because it may increase central nervous system side effects like dizziness and drowsiness.

Q: Is it necessary to have blood tests while using Risperidone?

A: Yes, regulatory documents recommend regular monitoring for potential metabolic changes. This monitoring typically involves checks for metabolic health, including blood glucose levels and lipid profiles (cholesterol), as well as white blood cell counts in specific circumstances.

Q: Can Risperidone be taken by people with a history of heart problems?

A: Official warnings state that the drug is subject to special considerations and caution in patients who have a history of cardiovascular disease (heart problems). This is primarily due to the risk of orthostatic hypotension, which is a drop in blood pressure that can cause dizziness or fainting.

Q: Is Risperidone considered safe for use in older adults?

A: The FDA has issued a Boxed Warning that the drug is not approved for treating behavioral problems in older adults with dementia. This is because patients in this population who take the medication have an increased risk of death and cerebrovascular events (e.g., stroke).

Q: Can taking Risperidone make me feel tired or drowsy?

A: Yes, official documents list sedation and drowsiness (somnolence) as very common adverse reactions reported in clinical trials. This effect has the potential to impair judgment and motor skills.

Q: What should I do if I experience dizziness after starting Risperidone?

A: Official warnings highlight that dizziness and lightheadedness are common, often resulting from a sudden drop in blood pressure (orthostatic hypotension) when standing up quickly. The risk may be higher during the initial phase of treatment.

Q: Is there a generic version of Risperidone available?

A: Yes, the active drug, risperidone, is widely available as a generic medication.

Q: How does Risperidone affect the chemicals in the brain?

A: Risperidone is described in official sources as working by changing the activity of certain natural substances in the central nervous system. Its mechanism involves modulating brain chemicals, primarily by acting as an antagonist (blocker) on dopamine and serotonin receptors.

Q: What are the most commonly reported side effects in official documents?

A: Regulatory documents list a range of common adverse reactions reported in trials. These include parkinsonism, akathisia (restlessness), sedation, dizziness, anxiety, constipation, dry mouth, increased appetite, and weight gain.

Q: How is Risperidone classified by regulatory bodies?

A: Risperidone is classified by regulatory bodies as an Atypical Antipsychotic, which is also referred to as a Second-Generation Antipsychotic (SGA).

Q: Can Risperidone cause changes in appetite?

A: Yes, increased appetite is listed in the official labeling as one of the commonly reported adverse reactions in clinical trials.

Q: Are there any specific safety warnings for people with diabetes taking Risperidone?

A: Official safety warnings note the risk of hyperglycemia (high blood sugar) and the development of diabetes mellitus. Regular blood glucose monitoring is recommended for patients with diabetes or risk factors for it.

Q: What is the risk of developing movement issues while on Risperidone?

A: The risk of movement issues is documented, with common adverse reactions including parkinsonism, akathisia (restlessness), and dystonia. A more serious, potential long-term risk noted in warnings is Tardive Dyskinesia, which involves involuntary, uncontrollable movements.

Q: Can Risperidone be used for conditions other than schizophrenia and bipolar disorder?

A: Yes, in addition to schizophrenia and bipolar I disorder, the oral formulation is indicated in the U.S. for treating irritability associated with autistic disorder in children and adolescents. This information is based on approved indications found in regulatory labeling.

Q: What is the evidence base for using Risperidone in children and adolescents?

A: Studies and official information confirm indications for use in adolescents and children, including for schizophrenia, bipolar I disorder, and irritability associated with autistic disorder. These uses are supported by evidence from controlled clinical trials.

Q: What is the purpose of taking Risperidone for irritability associated with autism?

A: Risperidone is officially indicated for the specific purpose of helping to control symptoms of irritability associated with autistic disorder. This includes managing issues such as aggression, temper tantrums, and sudden mood changes.

Q: What are the official restrictions on who can take Risperidone?

A: Official regulatory documents list hypersensitivity to the drug or its components as a contraindication. Furthermore, the drug is not approved for treating behavioral problems in older adults with dementia-related psychosis due to an increased risk of serious adverse effects.

Q: Is it common to feel restless or anxious when starting this drug?

A: Yes, regulatory documents list both anxiety and akathisia (a form of motor restlessness) among the commonly reported adverse reactions experienced by patients starting this drug.

Q: Are there any vitamins or supplements that interact with Risperidone?

A: Official information cautions against certain supplements that are strong CYP3A4 inducers, such as the herbal product St. John's Wort. These substances may reduce the concentration of Risperidone in the bloodstream.

Q: Can Risperidone cause changes in blood sugar levels?

A: Yes, the risk of hyperglycemia (high blood sugar) and the development of diabetes mellitus has been reported with this class of medication. The potential for these changes is why regular monitoring of blood sugar may be advised.

Q: Is Risperidone known to affect driving ability?

A: Regulatory warnings state that the drug has the potential to impair a person's judgment, thinking, and motor skills. Due to this risk, caution is advised when engaging in activities that require full alertness, such as driving or operating machinery.

Q: What research exists about the long-term effectiveness of Risperidone?

A: The regulatory approval for the drug's use in conditions like schizophrenia and bipolar disorder is based on evidence from controlled clinical trials. These studies demonstrate the effectiveness of the drug for its approved therapeutic indications.

Q: Why is regular monitoring often recommended for people taking Risperidone?

A: Regular monitoring is recommended due to the potential for certain side effects, known as metabolic changes. This includes checks for changes in blood glucose and cholesterol, as well as potential issues like hyperprolactinemia (high prolactin levels) and changes in white blood cell counts.

Q: Does Risperidone cause any issues with heat or sun exposure?

A: Official warnings indicate that Risperidone may interfere with the body's natural ability to regulate its internal temperature. This means it may be more difficult for the body to cool down when in very hot weather or during strenuous exercise.

Q: Does Risperidone have a potential for dependence or addiction?

A: According to regulatory documents, Risperidone is not listed as a controlled substance in the U.S. and has no known drug dependence potential officially noted in the product labeling.

Q: Can Risperidone affect fertility or have risks during pregnancy?

A: Official documents advise that the drug may cause problems in newborns if it is used during the last months of pregnancy. Furthermore, the elevated prolactin levels (hyperprolactinemia) associated with the drug may potentially affect fertility.

Q: What is the official guidance on consuming alcohol while on Risperidone?

A: Regulatory information states that alcohol should be avoided while taking Risperidone. This is because alcohol can enhance the central nervous system side effects of the drug, such as dizziness and drowsiness.

Q: Is it known if Risperidone can cause changes in vision?

A: Yes, official documents list blurred vision as one of the commonly reported adverse reactions. This is a potential side effect that may occur while taking the medication.

Q: Are there studies comparing Risperidone to placebo for approved uses?

A: Yes, the evidence supporting the drug's effectiveness for its approved uses (such as schizophrenia) comes primarily from placebo-controlled clinical trials that are cited in regulatory documents.

Q: Does Risperidone interact with herbal products like St. John's Wort?

A: Official documents caution that the herbal product St. John's Wort can act as a strong inducer of the CYP3A4 enzyme. This interaction may reduce the concentration of Risperidone in the bloodstream.

Q: How does official labeling describe the risk of high cholesterol with Risperidone?

A: Official labeling reports that undesirable alterations in lipid parameters (dyslipidemia) have been observed. These changes, which include increases in cholesterol and triglycerides, require monitoring.

Q: Is there a known effect of Risperidone on blood pressure?

A: Yes, the drug is associated with a risk of Orthostatic Hypotension, which is a sudden drop in blood pressure when a person stands up quickly. This can lead to feelings of dizziness or lightheadedness.

Q: Can Risperidone cause dry mouth or constipation?

A: Yes, official product information lists both dry mouth and constipation among the common adverse reactions reported in clinical trials.

Q: What is meant by the term 'antipsychotic' when describing Risperidone?

A: The term refers to the drug's classification as an Atypical Antipsychotic (or SGA). This means the drug helps to manage the symptoms of psychotic conditions like schizophrenia by affecting certain natural substances in the brain.

Q: Do official patient leaflets mention any changes to menstrual cycles?

A: Yes, official documentation notes the risk of hyperprolactinemia (elevated prolactin levels). This hormonal change has been associated with the potential for menstrual abnormalities in women.

Q: What is the difference between the tablet and the liquid form of Risperidone?

A: Both the tablet and the oral solution are approved for administration by mouth. The oral solution requires measuring with a dosing syringe and has specific restrictions, such as not being mixed with tea or cola, while the tablets have different handling requirements.

Q: Are there any contraindications listed for Risperidone use?

A: Yes, regulatory documents state that the medication is contraindicated if there is a known hypersensitivity (severe allergic reaction) to Risperidone or any of its ingredients. It is also not indicated for use in dementia-related psychosis.

Q: What happens in the body when Risperidone is started?

A: When starting the medication, it begins modulating key substances in the brain. Common initial effects reported include drowsiness and dizziness, which may be related to changes in blood pressure (known as orthostatic hypotension) when moving from sitting or lying down.

Q: Why do official sources state Risperidone should be used cautiously in people with kidney issues?

A: Official guidance recommends caution and a reduced starting dose for individuals with severe renal impairment (kidney issues). This adjustment is necessary because the drug's elimination from the body is decreased in this population.

Q: Can Risperidone be split or crushed, according to product information?

A: Product information for the Orally Disintegrating Tablet (ODT) explicitly states that it must not be split, broken, or chewed. Patients should refer to the official patient leaflet for instructions on splitting or crushing the standard tablet formulation.

Q: What is the earliest age for which Risperidone is indicated in some countries?

A: Official documentation, such as the FDA label, indicates the drug is approved for treating irritability associated with autistic disorder in children starting as young as 5 years of age. Other indications, like schizophrenia, are approved for older ages.

Q: Are there known effects of Risperidone on liver function?

A: Official documents advise a reduced starting dose for patients with hepatic impairment (liver issues). This is due to the potential for a higher concentration of the active drug to remain in the bloodstream in this population.

Q: What is the role of the active ingredient, risperidone, in the medicine?

A: The active ingredient, risperidone, is classified as an atypical antipsychotic and is the component responsible for the drug’s effects. Its role is to modulate key neurotransmitter activity in the brain to help manage the symptoms of approved conditions.

Q: How do regulatory agencies define the conditions Risperidone is used for?

A: Regulatory agencies specify the exact conditions and patient populations for which the drug is approved. These indications include treating Schizophrenia, Bipolar I acute manic or mixed episodes, and Irritability associated with Autistic Disorder, with defined age limitations for each.

How should Risperidone be stored and disposed of?

How to Store and Dispose of Risperidone

Official regulatory documents define specific storage and disposal requirements for Risperidone to maintain product stability and safety.

Storage Requirements

Dosage Form Temperature & Protection Stability Constraints
Oral Tablets & Solution Controlled room temperature (20 C to 25 C). Protect from light and freezing (solution). Discard oral solution 4 months after first opening.
Long-Acting Injection Refrigerated (2 C to 8 C) before mixing. Protect from light. Use reconstituted injection within 6 hours.
Orally Disintegrating Store in the original blister pack. Do not remove from blister until immediately prior to use.

All forms of Risperidone must be kept out of the sight and reach of children.

Disposal

Unused or expired Risperidone must be disposed of strictly according to local regulations and official procedures. The product should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Risperidone found in:

A-Z Index: